Market View 24th April, 2026

View on market: Volatility persists, eagerly searching for growth:

Global markets remained cautious as geopolitical tensions continued to impact sentiment. Futures for the S&P 500 and Euro Stoxx 50 moved lower, reflecting weak global cues. The focus stayed on geopolitics as Donald Trump said Israel and Lebanon will extend their ceasefire, although tensions related to Iran still remain and keep markets uncertain. Asian markets opened mixed. Japan’s Nikkei 225 and Topix moved higher due to improving inflation, while South Korea’s Kospi stayed weak and Kosdaq remained flat. US markets saw volatility as rising oil prices and concerns over supply disruptions pressured equities, leading to a fall in the S&P 500. However, Intel Corp stood out with strong gains on a positive outlook. Indian markets also ended lower, with BSE Sensex and Nifty 50 declining for a second session. Broader markets showed some resilience but still closed in the red.

Key Quarterly Results for Today:

ADANIGREEN, ATISHAY, ATUL, CANFINHOME, CHENNPETRO, DCBBANK, HINDZINC, INDUSINDBK, LODHA, LTF, M&MFIN, MRPL, OMEGAIN, ORGANICREC, PGCRL, RELIANCE, RPEL, SHRIRAMFIN, SPLPETRO, TANLA, TNPL, VINYLINDIA, WENDT, ZENSARTECH.

Economic Calendar:

• USD: Housing Price Index Data on 28^th April 2026.
• IND: Foreign Reserves Data on 24^th April 2026.
• USD: Monetary Policy on 29^th April 2026.
• IND: Industrial Production Data on 28^th April 2026.

BROKERAGE RADAR:

JEFFERIES ON INFOSYS:

Target ₹1235 Earlier Target ₹1290 Recommendation Hold, Growth concerns to weigh on stock, Manufacturing vertical and key regions drag growth:, FY27 growth guidance disappoints, See Multiple growth headwinds, Expect Infosys to deliver 7% recurring EPS CAGR, While 4% dividend yield caps downsides, worsening growth outlook limits upsides.

CITI ON CIPLA:

Target ₹1530 Recommendation Buy, Ventolin HFA Approval Boosts Pipeline Credibility, Expect the product to contribute US$50-70m in revenue, offsetting potential declines in US sales stemming from Lanreotide disruptions, Ventolin HFA approval is crucial for rebuilding investor confidence in Cipla’s complex generic pipeline, Upcoming key product launches to monitor include generic Advair, another undisclosed respiratory product, and a peptide product, likely Teduglutide.

MORGAN STANLEY ON CYIENT:

Target ₹1050 Recommendation Underweight, Q4-lower than expectations, Good growth in transportation and mobility segments, ahead of expectations, Decline in strategic units much sharper than estimates, Think the outlook is encouraging, but see it as a tall task in a volatile and challenging macro environment, Buyback may lend some support and the stock trades cheap, But investors would want to see consistent growth trends in the DET business before turning constructive on the name.

International Markets:

U.S & Europe:

*As per 24^th April.

Asian markets:

Stocks strong on Chart:

Commodities & Currency:

FIIs & DIIs:

News Updates:

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited (Elite Wealth Limited is wholly owned subsidiary of InCred Capital Financial Services Limited) does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

1. All of the views expressed in the report accurately reflect his or her personal views about any and all of

the subject securities or issuers; and

2. No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal

Entities Disclosures

Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
3. EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
4. EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
5. Compensation
6. EWL  or its associates have not received any compensation from the subject company in the past twelve months;
7. EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
8. EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
9. EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
10. EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
11. In respect of Public Appearances
12. EWL or its associates have not received any compensation from the subject company in the past twelve months;
13. The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL